Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Akloma Tinnitus, which later rebranded as Antinitus AB, was a Swedish medical technology company focused on developing non-invasive treatments for tinnitus. The company's primary product was Antinitus, a CE-marked skin patch designed to reduce the discomfort associated with tinnitus through a process the company called biomodulation. The patch featured a unique semi-transparent lens that modified incoming light into a specific signal intended to modulate nerve activity in the auditory system. Although the product was launched internationally and supported by clinical trials, the company faced financial difficulties in its later years. Antinitus AB was officially declared bankrupt in 2020, and its operations have since ceased.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Akloma Tinnitus.